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Human immunodeficiency virus type 2 (HIV-2) infections cause severe immunodeficiency in
humans, although HIV-2 is associated frequently with reduced virulence and pathogenicity
compared to HIV-1. Genetic determinants that play a role in HIV pathogenesis are relatively poorly
understood but nef has been implicated in inducing amore pathogenic phenotype in vivo. However,
relatively little is known about the role of nef in HIV-2 pathogenesis. To address this, the genetic
composition of 44 nef alleles from 37 HIV-2-infected individuals in Portugal, encompassing a wide
spectrum of disease associations, CD4 counts and virus load, has been assessed. All nef alleles
were subtype A, with no evidence of gross deletions, truncations or disruptions in the nef-encoding
sequence; all were full-length and intact. HIV-2 long terminal repeat sequences were conserved
and also indicated subtype A infections. Detailed analysis of motifs that mediate nef function in
HIV-1 and simian immunodeficiency virus, such as CD4 downregulation and putative SH2/SH3
interactions, revealed significant natural variation. In particular, the central P104xxPLRmotif exhibited
wide interpatient variation, ranging from an HIV-1-like tetra-proline structure (PxxP)3 to a disrupted
minimal core motif (P104xxQLR). The P107RQ substitution was associated with an asymptomatic
phenotype (Fisher’s exact test, P=0?026) and low virus loads. These data indicate that discrete
differences in the nef gene sequence rather than gross structural changes are more likely to play a
role in HIV-2 pathogenesis mediated via specific functional interactions.
INTRODUCTION
Human immunodeficiency virus type 2 (HIV-2) is the
second human retrovirus to be causally linked to AIDS
(Clavel et al., 1986). HIV-2 has remained restricted largely to
west Africa (reviewed by Schim van der Loeff & Aaby, 1999;
Bock & Markovitz, 2001), unlike HIV-1, which has spread
rapidly to all parts of the world. HIV-2 has been associated
especially with former Portuguese colonies, particularly
Guinea Bissau, which reports the highest prevalence of
HIV-2 in west Africa: up to 8% of the population is infected
with HIV-2 but is accompanied by relatively low rates
of excess mortality (Poulsen et al., 1997; Berry et al., 2002).
In Europe, Portugal reports the highest prevalence of
HIV-2 infections, with 4% of notified AIDS cases due
solely to HIV-2 (National AIDS Commission, 2002; Soriano
et al., 2000).
Differences in the natural history between HIV-1 and
HIV-2 are well documented (Marlink et al., 1994; Whittle
et al., 1994), although the mechanism(s) that governs
the maintenance of an attenuated phenotype for extended
time-periods in a large proportion of HIV-2-infected
individuals is not fully understood. Differences in virus
subtype may provide one explanation, in particular of HIV-
2 variants that resemble simian immunodeficiency virus
(SIVSM) infections, which appear apathogenic (Chen et al.,
1997; Gao et al., 1994; Wolf et al., 2001; Yamaguchi et al.,
2000), but these are few in number and distinct from
infections due to the more pathogenic subtypes A and B.
Isolation of virus from asymptomatic HIV-2-infected
individuals is more difficult than for HIV-1 (Schulz et al.,
1990; Simon et al., 1993); many strains are characterized by
low levels of cytopathogenicity and reduced virulence. HIV-
2 strains, however, exhibit the capacity to utilize a broad
spectrum of co-receptors and do not appear to be restricted
in their cell tropism (reviewed by Reeves & Doms, 2002).
The failure of HIV-2 to develop into a pandemic and the
more attenuated phenotype in vivo is correlated with low
levels of plasma HIV-2 RNA (Berry et al., 1998, 2002;
Andersson et al., 2000; Ariyoshi et al., 2000; Popper et al.,
1999) and when associated with high CD4 counts, low
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plasma viraemia is predictive of normal survival (Berry et al.,
2002). Conversely, advanced HIV-2 infections and disease
are associated frequently with high virus load (Ariyoshi
et al., 2000; Berry et al., 1998, 2002), with HIV-2 plasma
RNA levels representing an independent predictor of disease
progression. Hence, host or viral genetic factors that
increase virus replication/virus load are likely to have a
direct impact on the pathogenesis of HIV-2. Unlike HIV-1
and SIV, the role of nef in the differing phenotypes of HIV-2
infections has not been studied as extensively.
Nef, an auxiliary protein that is highly conserved among
different primate lentiviruses, regulates virus replication and
acts as an immune modulator (Collette, 1997). Genetically
and structurally, HIV-2 nef is more similar to SIVMAC/SM nef
than to HIV-1 nef and is approximately 260 amino acids in
length. In vivo studies of SIVMAC in Asian macaques indicate
that an intact nef gene is essential for full disease induction
and maintenance of high virus load (Kestler et al., 1991).
Virus populations attenuated due to the disruption of nef
have been demonstrated in both SIV-infected macaques
(Whatmore et al., 1995) and long-term survivors with
HIV-1 (Deacon et al., 1995; Michael et al., 1995; Geffin et al.,
2000; Learmont et al., 1999). However, no consistent
relationship between nef disruption and prolonged survival
in HIV-1-infected individuals has been shown (Carl et al.,
2000a, b; Kirchhoff et al., 1999; Mourich et al., 1999),
suggesting a complex role for nef in the development of
human AIDS. Studies of transgenic mice have also indicated
a major role for nef in inducing a pathogenic phenotype
(Hanna et al., 1998, 2001). One previous report based on
a mixture of HIV-2 subtypes indicated a higher proportion
of truncated nef alleles in asymptomatic HIV-2 infections
than expected for HIV-1, an observation that might explain
differences in pathogenesis (Switzer et al., 1998) and which,
therefore, warrants further investigation.
Nef accomplishes different functions for virus infectivity
and virulence (reviewed by Piguet & Trono, 1999; Fackler &
Baur, 2002). HIV-1 nef downregulates cell surface CD4
expression and probablyMHC class I expression (Greenberg
et al., 1997; Mangasarian et al., 1999), connecting the
viral receptor and cellular components by adaptor protein
(AP)-forming complexes with clathrin-coated pits (Foti
et al., 1997), which mediate endocytosis (Piguet et al., 1998).
Di-leucine-based motifs in the C-terminal part of nef are
important in this process (Craig et al., 1998). In SIV nef,
both tyrosine- and leucine-based motifs are involved in
CD4 downmodulation (Bresnahan et al., 1999). Although
AP interactions vary for different virus–host interactions
among different primate lentiviruses (Greenberg et al., 1997;
Karn et al., 1998; Lock et al., 1999), combined data from
functional studies indicate the same net effect of nef-induced
CD4 downregulation. Other cellular partners such as
V-ATPase and b-COP (Piguet et al., 1999) may also be
involved in these complex processes.
Nef augments virus infectivity in vivo by activating target
cells through T-cell signalling and signal transduction
pathways (Bell et al., 1998; Simmons et al., 2001;
Manninen et al., 1998; Fackler et al., 2001; Fackler &
Baur, 2002). Canonical proline-rich (PxxP) regions in nef
(Saksela et al., 1995) mediate interactions with Src homo-
logy region 3 (SH3)-binding domains for Src family kinases
such as Hck, Lck and Fyn (Cheng et al., 1999; Lee et al., 1995;
Collette et al., 2000). In HIV-2 and SIV nef, the core SH3-
binding domain is usually represented by a minimal binding
consensus motif (P104xxPLR), although this is typically a
tetra-proline structure (PxxP)3 in HIV-1.
In this study of HIV-2 infections, we describe in detail
HIV-2 nef sequence variability in Portugal and its relation
to putative nef function and pathogenesis.
METHODS
Study population. Whole blood was collected between 1994 and
2000 from 37 individuals living in Lisbon, Portugal. These indivi-
duals were identified as having HIV-2 infection using a range of
serological and genome detection methods and represented a broad
cross-section of HIV-2 infections in this country. A wide range
of epidemiological and clinical data was collected, including age,
gender, ethnic status, route of transmission and country of infection
(summarized in Table 1). Of the 37 individuals studied, only seven
received anti-retroviral therapy, three (117, 281 and 956) to treat
progressive HIV-2 infection and the other four (1227, 1570, 1428
and 1378), who received transient anti-retroviral therapy, to prevent
vertical transmission around the time of birth. All four women
receiving therapy to prevent HIV transmission were asymptomatic.
HIV-2 viral RNA load was only measured subsequently in three
women who had received transient drug therapy (1227, 1570 and
1428) and from whom plasma was available.
Amplification of HIV-2 nef and nef/LTR. Peripheral blood
mononuclear cells (PBMCs) were isolated by Ficoll–Hypaque density
gradient centrifugation. Cellular DNA was prepared by proteinase
K treatment, phenol/chloroform purification and ethanol precipita-
tion. DNA resuspended in nuclease-free water was quantified by
spectrophotometry. HIV-2 proviral sequences were amplified
initially using primers located in the LTR and pol (integrase), as
described previously (Berry et al., 1994). nef and nef/U3 LTR regions
were amplified using different primer combinations. HIV-2 nef
was amplified using outer primers [sense, 59-GAGCTCGGTACCC-
GGGATGGGTGCGAGTGGATCCAA-39 (nt 8503–8538); antisense,
59-TCTAGAGTCGACCTGCAGGGTATCCCTCTTGCTTTC-39 (nt
9262–9287)], numbering based on HIV-2ISY (GenBank accession
no. J04498), and the nef/LTR to the R region was amplified
using a nested PCR protocol with outer [sense, 59-AAGGGC-
TATAGGCCWGTDTTCT-39 (nt 8234–8254); antisense, 59-
TGGTGAGAGTCTAGCAGGG-39 (nt 9534–9552)] and inner [sense,
59-GCCCAACTGCAATATGGGTGCGAGT-39 (nt 8506–8530); anti-
sense, 59-AACACCCAGGCTCTACCTGCT-39 (nt 9513–9533)] primers.
Amplifications were performed in 100 mM KCl, 20 mM Tris/HCl
(pH 9), 0?1 mM EDTA, 1 mM DTT, 0?5% Tween 20, 50% (v/v)
glycerol, 1?5 mMMgCl2, 200 mM of each dNTPs (dATP, dTTP, dCTP
and dGTP), 300 nM of each internal primer pair and either 2?5 units of
AmpliTaq Gold DNA polymerase (Perkin-Elmer) or 2?6 units of Taq/
Pwo using the Expand High Fidelity PCR system enzyme mixture
(Roche). Primary amplifications were performed as follows: 94˚C for
10 min for 1 cycle and 94˚C for 30 s, 53 C˚ for 45 s and 72˚C for 1 min
30 sec for 35 cycles. Nested reactions with inner primers were 94˚C for
15 s, 50 C˚ for 45 s, 72˚C for 1 min 30 s for 35 cycles with a final
extension step at 72 C˚ for 7 min. Products were visualized on 1?75%
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Table 1. Epidemiological, immunological and virological characteristics of the 37 HIV-2-infected individuals studied
NA, Not available.
Reference
(individual)
Country of
infection
Race Sex Age Route of
infection
Clinical
symptoms
Anti-retroviral
therapy
Plasma HIV-2 viral
RNA load (copies ml21)
CD4 count
(cells mm23)
Additional information
268 Cape Verde B M 55 Heterosexual Yes No 200 340 Lung cancer
423 Guinea Bissau B M 47 Heterosexual Yes No <200 966 Tuberculosis
379 Portugal W M 37 Heterosexual Yes No 62 950 366 Tuberculosis
546 Portugal W F 65 Blood transfusion Yes No <200 297 Infected 1987/Died 2000
1069 Africa B F 67 Blood transfusion Yes No 34 750 NA Infected 1979/Died 1999
138 Africa B M 44 Heterosexual Yes No NA NA Tuberculosis
984 Portugal W F 45 Blood transfusion Yes No 8 830 195 Infected in 1978
117 Guinea Bissau B M 8 Blood transfusion Yes Yes NA 199 Infected in 1986
281 Guinea Bissau B M 42 Heterosexual Yes Yes NA 46 Tuberculosis
956 Guinea Bissau B F 32 Heterosexual Yes Yes NA NA Died in 1999
280 Guinea Bissau W M 48 Heterosexual Yes No NA NA
120 Angola B F 32 Blood transfusion No No NA NA
MP Portugal B F 30 Heterosexual No No <200 610 Prostitute
741 Portugal W F 27 Heterosexual No No <200 NA
1227 Africa B F NA Heterosexual No Yes <200 NA Study of HIV vertical transmission
1268 Guinea Bissau B F 21 Heterosexual No No 3 730 529
BL Guinea Bissau B M 48 Heterosexual No No <200 288
794 Cape Verde B F 30 Heterosexual No No <200 NA
293 Guinea Bissau B M 32 Heterosexual No No NA 519 Diabetic
483 Africa B F 24 Heterosexual No No 200 NA
1139 Portugal W F NA Heterosexual No No <200 NA
1147 Cape Verde B M 53 Heterosexual No No 2 259 407
1570 Guinea Bissau B F NA Heterosexual No Yes <200 427 Study of HIV vertical transmission
1215 Portugal W F NA Heterosexual No No <200 430
1320 Africa B F NA Heterosexual No No 200 444
1544 Cape Verde B M 63 Heterosexual No No NA 730
1428 Portugal W F NA Heterosexual No Yes <200 NA Study of HIV vertical transmission
292 Portugal W F 45 Heterosexual No No <200 NA
1096 Portugal W M 16 Blood products No No <200 902 Haemophiliac
1543 Guinea Bissau B F 28 Heterosexual No No <200 993
LF Portugal W F 44 Heterosexual No No 400 437
EP Portugal W F 52 Heterosexual No No <200 490
1567 Portugal W F 26 Heterosexual No No 3 491 1346 IV drug user
PL Guinea Bissau B M 45 Blood transfusion No No 6 920 127 Infected in 1973
511 Portugal W F 36 Heterosexual No No 500 473
223 Guinea Bissau B F 40 Heterosexual No No NA 161
1378 Africa B F NA Heterosexual No Yes NA NA Study of HIV vertical transmission
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agarose gel containing ethidium bromide (0?5 mg ml21). Aliquots
(2–10 ml) containing 0?6 mg extracted genomic DNA were used in
primary amplifications and 2 ml of first-round product was used as
template for second-round PCR.
Purification of PCR fragments and sequencing. PCR products
were purified for sequencing reactions by precipitation with 20%
PEG8000 in 2?5 M NaCl. Alternatively, oligonucleotide primers were
separated from the PCR product by gel filtration using a Sepharose
CL4B column (Pharmacia) under gravity (Almond et al., 1992).
Direct sequence analysis of both strands was determined using a
modified Sequenase (Amersham) protocol and T7 polymerase
(Pharmacia). Terminations were carried out at 50˚C. ABI PRISM
Big Dye Terminator kits were used with a cycling profile recom-
mended by the manufacturer. Additional sequencing primers to
those used to generate the product were at conserved sites within nef
in either the sense orientation [59-GGGCTACGAGAGAGACTCTT-
39 (nt 8561–8580), 59-GCGAGTGGATCCAAGAAG-39 (nt 8525–8542),
59-GATAAGGGGGGACTGGAAGGGATG-39 (nt 8891–8914), 59-
CAGCAAGGAGACTTTATG-39 (nt 8700–8717) and 59-TGGCT-
ATGGAAGCTAGT-39 (nt 9035–9051)] or the antisense orientation
[59-TGCTTTCAGTTTTGCCTTC-39 (nt 9250–9268), 59-GTACTAG-
CTTCCATAGCC-39 (nt 9036–9053), 59-CATCATCTGAATCTACAT-
39 (nt 8785–8801) and 59-GTTCTCCATGGGGTATTC-39 (nt
8716–8733)], also numbered according to HIV-2ISY. Sequence
contigs were generated using the Gap4 program (Staden software
package; Bonfield et al., 1995) from a consensus generated from
both sense and antisense strands and analyses were performed using
the GCG software package and the CLUSTAL W program to generate
multiple sequence alignments (Thompson et al., 1994).
Cloning of nef alleles. PCR products from a selected number of
individuals were cloned into the pGEM-T plasmid vector with a TA
Cloning kit (Promega). Ligated DNA was transfected into JM109
cells (Promega) and plasmid DNA purified using QIAprep kits
(Qiagen). Clones were sequenced as described above.
Phylogenetic analysis. Nucleotide sequences were aligned and
evaluated with CLUSTAL W and phylogenetic trees were constructed
from the matrix built by the neighbour-joining method (NEIGHBOR,
version 3.5c; Felsenstein, 1989). Nucleotide substitution rates per
site were estimated for each pairwise sequence comparison on the
basis of the Kimura two-parameter model using DNADIST. Bootstrap
analysis was performed with SEQBOOT and CONSENSE with 100
re-samplings. Trees were rooted with SIVMM239 and drawn with
NJPLOT; reference sequences were obtained from the Los Alamos
database. Nucleotide sequences reported in this study have been
submitted to the EMBL nucleotide sequence database (accession nos
AJ344369–AJ344415). Epidemiological and clinical aspects were
evaluated statistically with SPSS (statistical package for social science).
Quantification of HIV-2 RNA levels in plasma. EDTA-treated
plasma samples were stored at 280˚C until levels of HIV-2 viral
RNA were assessed using a quantitative RT-PCR assay (Berry et al.,
1998). In brief, RNA was extracted according to the method of
Boom et al. (1990) and RT-PCR performed, in duplicate, with HIV-
2-specific LTR oligonucleotide sequences in single-tube assays using
Titan reagents (Roche). Amplification products were quantified by
chemiluminescence using an internal HIV-2 probe linked to alkaline
phosphatase (Oswel). The reliable level of sensitivity of the assay
was 200 copies ml21 using an input plasma volume of 100 ml. For
statistical analyses, plasmas with <200 copies ml21 were assigned
an arbitrary value of 20 copies ml21.
RESULTS
Epidemiological, clinical and virological
characteristics of the study population
Of the 37 HIV-2-infected individuals studied (Table 1), 24
(64?9%) were female and 13 (35?1%) were male, with a
mean overall age of 39?4 years (n=37, range 8–67 years).
The main route of transmission was heterosexual (30/37,
81?2%), the remaining seven being transfusion-associated
infections. HIV-2 infection was acquired in Portugal in
14 (37?8%) individuals; the other 23 (62?2%) infections
were most likely acquired in Africa: Guinea Bissau (n=12,
32?4%), Cape Verde (n=4, 10?8%), Angola (n=1, 2?7%)
or an unidentified African country (n=6, 16?2%). Follow-
ing clinical examination, 11/37 (29?7%) were symptomatic
(HIV-related illness/AIDS) and 26 (70?3%) were asymp-
tomatic, including three individuals (1069, PL and 280) who
had been infected for 20 years or more. CD4 lymphocyte
counts and HIV-2 viral RNA loads were available for the
majority of, but not all, individuals. In the asymptomatic
group, mean CD4 counts were 548 (n=17, range
161–1346 cells mm23) and mean HIV-2 RNA levels were
817 copies ml21 (n=21, range<200–6920). In the symp-
tomatic group, mean CD4 counts were correspondingly
lower at 328 (n=8, range 46–966 cells mm23) and the
mean HIV-2 viral RNA load was 20 times higher than that in
the asymptomatic group at 17 051 copies ml21 (n=7, range
<200–62 950).
HIV-2 nef sequences in Portugal are subtype A
and full-length
A total of 44 nef/LTR proviral sequences spanning the entire
nef gene were amplified from 37 HIV-2-infected individuals
(792 bp, Fig. 1). Consensus sequences derived from each
of the 37 individuals from bulk product were substantially
full-length with little evidence of deletions, truncations or
other disruptions to nef. Predicted amino acid sequences
(see below) suggested a functional HIV-2 Nef protein to be
present in all individuals studied, irrespective of any other
factor. Subsequent bleeds from six individuals yielded a nef
sequence with few nucleotide or amino acid differences
from the first sequence; hence, comparisons of nef variation
were made on the first, bulk amplification of each patient.
This observation was confirmed further by dilution experi-
ments of template DNA. Phylogenetic relationships between
Portuguese nef sequences were compared with HIV-2
subtype A (HIV-2ROD, HIV-2BEN, HIV-2ALI, HIV-2ISY and
HIV-2ST), subtype B (HIV-2D205/ALT, HIV-2UC1 and HIV-
2EHO) and SIVMM239 (Fig. 1). All Portuguese sequences
were HIV-2 subtype A, with no other HIV-2/SIVSM subtypes
(B–G) identified. No phylogenetic relationship was estab-
lished between nef sequence and disease status and no
statistical link between HIV-2 nef sequence and route of
transmission, either sexual or blood transfusion, was
apparent (data not shown).
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Analysis of LTR sequences
Sequence data for the non-overlapping U3 region of
the LTR was available for 31 individuals, indicating
no disruptions to the structure of the LTR. Comparisons
of the core promoter and enhancer elements important
in the transcriptional activity of the LTR, including
PuB-1, PuB-2 p-ets, peri-kB and NF-kB sites up to the
Sp1 sites and TATA box, indicated further sequences to
be subtype A with high levels of sequence conservation
in vivo. Sequences are not shown but have been filed
in GenBank.
HIV-2 nef amino acid variation
Alignment of predicted amino acid sequences for the entire
nef ORF for all 37 Portuguese HIV-2-infected individuals
is shown in Fig. 2; the first sequence obtained for each
individual is presented. The Portuguese HIV-2 nef con-
sensus sequence was also compared with other lentivirus
nef sequences, including a prototypic HIV-1 group M
virus (HIV-1LAI), SIVCPZ (Gab), from chimpanzees, and
SIVMM239, an experimental infection of Asian macaques
derived originally from SIVSM. Predicted coding sequen-
ces were compared for 10 putative regions considered
important for HIV-1, HIV-2 or SIV nef function (Fig. 2).
Throughout nef, a number of key regions were conserved
among the Portuguese sequences, irrespective of clinical
status, virus load or CD4 count, and deletions that might
disrupt such sites were not evident. Moreover, only one
patient showed evidence of a deleted nef sequence: patient
379 (symptomatic/AIDS) exhibited a nef deletion of 8 aa
downstream of a suggested N-terminal RNA-binding motif
(Echarri et al., 1997).
The myristoylation signal (aa 1–6, HIV-2 consensus
GASGSK) was 100% conserved and GPG(V/T) sequences
predictive of a b-turn were also conserved, with a T present
in one AIDS patient (281) and in six asymptomatic indivi-
duals. Comparative analyses of other regions identified
as being relevant to nef function exhibited a more com-
plex pattern of variation, particularly the SH3-binding
PxxP motif, the di-leucine-based region important for
downregulation of CD4 (in HIV-1 the ENTSLL motif)
and sites for putative SH2 interactions based on tyrosine-
sorting signals.
(i) Analysis of HIV-2 nef for putative tyrosine-based
sorting motifs. The canonical tyrosine-based sorting
motif Yxxw, present as Y28GRL and Y39SQS in SIVMAC239
and Y39SRF in HIV-2ROD, is Y
39LQS in these Portuguese
sequences, with changes to this basic configuration infre-
quent. Patient 984, an AIDS patient with a CD4 count of
195 and viral RNA levels of 8830 copies ml21, exhibited a
RRY mutation at position 24; patients LF and PL exhibi-
ted CRY mutations at position 28. However, additional
tyrosine-based motifs in HIV-2, such as YE nef described
for SIVMAC239, were not present in any HIV-2 sequences,
including those in the symptomatic group. Interestingly,
the most conserved tyrosine residue at position 39 was
mutated in two AIDS patients (117-1 and 1378) to pheny-
lalanine, serine or cysteine. There was no apparent rela-
tionship between disease status and tyrosine-based motifs.
(ii) Di-leucine-based motifs for CD4 downregulation.
Cellular di-leucine-based sorting pathways required for
CD4 downregulation in HIV-1 are characterized by a
core hexameric motif ENTSLL (ExxxLL), which conforms
to the consensus E/DXXXLw found in cellular transmem-
brane proteins (Craig et al., 1998). HIV-2 nef sequences
analysed for a comparable motif (L198L199) indicated
variation at only L199, present as leucine, valine or
Fig. 1. Phylogenetic tree based on 44 nef/LTR sequences
derived from proviral DNA fragments amplified by PCR from
PBMCs of 37 individuals, five reference HIV-2 subtype A
sequences (HIV-2BEN, HIV-2ALI, HIV-2ISY, HIV-2ROD and HIV-
2ST) and three reference sequences for subtype B (HIV-2EHO,
HIV-2ALT/D205 and HIV-2UC1). SIVMM239 was used as the out-
group sequence. A second sequence obtained from each of
six individuals is indicated (1139-1/1139-2, 1147-1/1147-2,
LF-1/LF-2, MP-1/MP-2, 281-1/281-2 and 117-1/117-2).
Prefixes of ‘a’ and ‘s’ indicate asymptomatic and symptomatic,
respectively. Samples suffixed ‘dil’ indicate that the sequence
was derived from a 1/10 dilution of the original DNA material.
Bootstrap values above 80%, based on 100 replicates, are
indicated at the branching nodes. Evolutionary distances were
estimated using the Kimura two-parameter model and genetic
relationships were determined using the neighbour-joining
method. Bar, 10% sequence divergence.
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methionine, with L198 conserved throughout. Interest-
ingly, patients 280, 120, 281, MP and 956 grouped into
an EANCLL configuration, three of which (281, MP and
956) had tetra-proline (PxxP)3 motifs. Overall, 15/37
(40?5%) individuals had the L198L199 motif, with seven
(19%) substituting the leucine at position 199 for valine
and 15 (40?5%) for methionine. The number of LL
motifs was distributed evenly between asymptomatic and
symptomatic groups at eight and seven, respectively, form-
ing an asymptomatic consensus of LM and symptomatic
consensus of LL. Interestingly, the region immedi-
ately preceding this was relatively heterogeneous across all
           1                    2                  3
HIV-1 LAI MGGKWSKSSVIGWPTVRERMRRAEP AADRVGAASRDLEKHGAITSSNTAA TNAAC********************
SIVCPZGAB MGTKWSKSSLVGWPEVRRRIREAPT AAEGVGEVSKDLERHGAITSRNTPE TNQTL********************
SD MM 239 MGGAISMRRSRPSGDLRQRLLRARG ETYGRLLGEVEDGYSQSPGGLDKGL SSLSCEGQKYNQGQYMNTPWRNPAE
HIV-2ROD  MGASGSKKHSRPPRGLQERLLRARA GACGGYWNESGGEYSRFQEGSDREQ KSPSCEGRQYQQGDFMNTPWKDPAA
PORT-CON  MGASGSKKRSRPSRGLQERLLRARG GTCGGHWDESGGGYLQSQEGSGREQ -SPSCEGQRYQQGDFMNTPWRTPAA
                                 25                        50                        75
     280  ----------K--SD---------- -P---R--N--E------G------ N--------------------N--G
     223  --------H-S-----R----Q-H- --S--Q-G---E------G------ R-------HISP---------N--T
   281-1  -------R---SLQ----------- E----RCN--E------H------- R----------E------------T
     120  -----------SLQ----------- E----RCNA-E------H------- R----------E---------N---
    MP-1  -------RP--SLQE-R---F--A- E----RCNK-E-----FH---D--- R----------E--------G---V
     956  ----------E--QR-R-------- E-----CSQ--E--S--HG--D-G- NA-----------------------
     741  -------EH-K-----R-------A E-S--GYKDL--E------E----- R---Y-----R---------KD-T-
    1227  --------Q-K-----R-------- E-S-EG-R-L--E------E----- R-R----R-----E------KD--P
     268  --------P---------------A -----Y-Q-L--E-SR---E----- R-------------------KD-S-
    1570  ------------LQ---Q------A -A---Y---L--E------------ KL---------------------T-
    1215  -------------Q---Q------A -A---Y-N-L--E-S---------- K-------Q----------------
    1320  -------R--K--Q---Q------A -A----------V-SR--------- K-------Q---------------T
    1544  --------H-K------Q------A -A-------L--E--RF-------- K--------------------N--T
     483  --------P---P-----------A -----Y-E-L-EE----------G- K-------K------------A--I
     293  --------P---P-----------A -A------RL-EE----------G- K----------------------ET
  1147-1  --------P---P-----------A -A-----EQLE-------------- KL-----------E----------T
  1139-1  --------L---P-----------A -A-------L--E------E-D-G- K-------------------K---I
      BL  ----------K-------------A -A-------L--K-S----R----- K--------------------H---
     794  -------------Q---Q------A ----EY-N-L--E------------ R---------R----------D---
     423  ------------------------A -----Y-G-LA-E------E--K-- K------R------------KD--T
     379  ------------------------A -----Y---L--Q-S-F--E-D--- K--------------------....
    1428  -------T----------------A -A-----G-LE-E-S-F-GE----- K----------A------------T
     292  ------------P-----------A -----Y-K----Q-SRY--E-D--- R------------E-------N--T
    1096  -------------QE--Q-----Y- E----QHGG---------------- N---------R--------------
     984  -------------QE--Q-----Y- E----QHGG---------------- N---------R--------------
    1543  ------------LQ----------- -----QCSG-E-----------K-- N------------------------
    LF-1  ----------K-LQ--R----Q--- E-Y--RCGG-D-----FH-E----- N------------------------
     138  ------------LQ-------Q--- E---R-C-G-E-R--RF-------- NL-------------------A--T
      EP  -------T--------R----Q-C- E-S--R-GG-E-------------- NL-------------------N--T
    1268  ----------K---E---------- E-----Y-S-Q------------G- R-------K------V-----A--T
    1567  --------Q-------R-----T-E -----QSHG-E-------GE---G- S------------------------
      PL  ----------E-----R-------- E-Y--RCNG-E-E------------ K-L-------N---------KD-TS
     546  ----------K--Q-------QTH- -A----CNG-E-------GE---G- N------------------------
     511  ----------K-----R-------- -A--R-CNG-E-E-S-FLGE-DKG- N-------Q----------------
    1069  --------H-K-LQ--R----Q--- -----RSN--E-E-----GE----- N-----------------------G
   117-1  --------H-K--Q--R-------- E-----S-G-AERC-----E---G- N-----------------------G
1378 ----------T-L--------QTG- RDLW-RCNR--E-SSRF-GE----- N---------NP---V---Q----P
       4       5            6                               7
*********AWLE AQ-EEE-EVG FPVTPQVPLRPMTYKAAVDLSHFLKE KGGLEGLIHSQRRQDILDLWIYHTQ
*********AWLE EM-DNE-EVG FPVRPQVPTRPMTYKAAFDLSHFLKE KGGLEGLVYSRRRQEILDLWVYHTQ
EREKLAYRKQNMDDIDESDDDLVGV SVRPKVPLRTMSYKLAIDMSHFIKE KGGLEGIYYSARRHRILDIYLEKEE
EREKNLYRQQNMDDVDSDDDDQVRV SVTPKVPLRPMTHRLAIDMSHLIKT RGGLEGMFYSERRHKILNIYLEKEE
EGEKNLYRQQNMDDVDSDDDDLVGV PVTPRVPLRAMTYRLAIDMSHRIKE KGGLEGMFYSERRHRILDIYLEKEE
                      100                       125                       150
-E--K-----------E---NQ--- S--------T---K----------- --------------K----------
-E--KS---------------Q--- S------------Q------FD--- ------II--G--Q----------K
-R--E--K--------L----Q--F ----K----P---K--------L-- ------I---H---K---L------
-R--EM----------L--N-Q--F ---S-----P---K--------L-- ----------Q-------L------
-R--E-HK--------L--N-Q--F ----K----P---KM-------L-- ------L---Q---E---L------
----ER-K-------------S--- ---------P---K----------- ----------A--------------
--KE-S------------------F --V---Q--E----R---------- R---D----------------QN--
--KE-A------------------- ---------E----R---------D --------------K------QN--
VRKE-S------------------- S--------E----R------L--D ---------------------QN--
---R-A-K-------------Q--- S-----Q--G---K----------- ----------D---K----------
----KA-------------E-Q--- S-----Q--G---K----------- ----------D---K----------
-R-RDA-K-------------Q--- S--------G---K----------- -------------------------
-K--IE---------------Q--- H-K------E--TK----------- --------------K---T---N--
---RSA-K-------------Q--- ------------H--------L--D -------------------------
---R-A-K-------------Q--- -----T---P-----------L--D --------------K----------
-----A-K-------------Q--- A---K-Q-------M------L--D -----------K----------N--
---RKA-K-------------Q--- S-R-K-Q--------------L--D ----------D-------T------
-----S------------------- S---KT---E--------------D -------------------------
-----S------------------- -----TQ--E--------------D -------------------------
-----P------------------- ----K-------------------D -------------------------
....-TNK----------N------ ---------P--------------D --------------N----------
-----P-K-------------Q--- --S------E--------------- ------------------L------
-.-G-----H-----------Q--- S--S--------HQ----------N --------------K----------
-K--E---------------N---- S------------K----------- ------------------L------
-K--E---------------N---- S------------K----------- ------------------L------
-K-NQ--K-------------Q--- ----Q----Q---K----------- Q-------------------F--K-
-R--EM-K------------NQ--- S---K----------------L--D -------------------------
----R-------------------- H------V------M------L--- -----------K-------------
DE--RS----------L-------- A---K----T-----------E--N ----------D--------------
-R-NKQ-K----------------- S-----Q------K----------D -------------------------
-R--E--K----------------- ------Q--E---KM---------- -----------------------Q-
-Q--KQ------------------- S-V---Q--I---K----------- ---------N----K----------
-R--A-------------------- S--------P--------------D ---------C---------------
-K--A--K----------------- ---------P---KM---------- ------I-H--E-Q-----------
-R-RAM-K--------AE------- --R------T---K----------- -------------------------
.R-GE--K----------------C ----KA------H--------L--- -------------------------
---SK--------A--A-------- S-R-----------M------L--Q E-----------------M---N--
       
                                               8           9         10
HIV-1 LAI GYFPDSQNYTPGPGVRYPLTFGWCY KLVPVEPDKIEEANKG**ENTSLLH PVSLHGMDDPE****REVLEWRFDS
SIVCPZGAB GFFPDWQNYTTGPGTRFPLCFGWCF KLVPLTEEQVEQANEG**DNNCLLH PICQHGMEDED****KEVLHWQFDR
SD MM 239 GIIPDWQDYTSGPGIRYPKTFGWLW KLVPVNVSDEAQED****EEHYLMH PAQTSQWDDPWGEVLAWKFDPTLAY
HIV-2ROD  GIIADWQNYTHGPGVRYPMFFGWLW KLVPVD VPQ***EGEDTETHCLVH PAQTSKFDDPHGETLVWEFDPLLAY
PORT-CON  GIIPDWQNYTHGPGIRYPKFFGWLW KLVPVDTVPQ***EGEDTETHCL-H PAQTSRFDDPHGETLVWRFDPMLAY
                                175                       200                       225
     280  --L-------Y---V----T----- ------LPQ....RE--N-AN--L- ---------------R-K------H
     223  --------------V---------- ------VS-....-------Y--M- ---------------M-K-------
   281-1  ---A----------T---M------ ------.--R...-E-ED-AN--L- ---------Q-----------T---
     120  ---A----------T---M------ ------.--G...-E-NN-AN--L- ---------Q-----------T---
    MP-1  --------------T---M------ ------.--R...-E-EN-AN--L- ------L--Q-----------T---
     956  ---A----------I----T----- ------.A--...-E-EN-AN--L- --------------------S----
     741  --------------V---M------ ------.-S-...-EG-----Y-V- -----K------Q------------
    1227  --------------I---M------ ------.---...----I-----M- ------------Q------------
     268  --------------I---------- ------.-S-...AE--------M- -----Q---I---------------
    1570  --------------V---------- ------.---...--N-------M- -----H-------R-------K--H
    1215  --------------I---------- ------.---...--NG------M- -----H---------------K--H
    1320  --------------V---------- ------.---...--N-------M- ---I-H---Q-----------K--H
    1544  --------------I---M------ -----N.N--...DEN-------M- -----HL-------------SK---
     483  --------------I---MH----- ------.---...--K-------M- ---V-----------L--------H
     293  --------------T---M------ ------.---...--G-------V- ---V-K-------------------
  1147-1  --------------V---------- ------.---...----I-----M- ---IG--------------------
  1139-1  --------------T---M------ ------.---...---..-----V- ---V-K------------------H
      BL  ---A----------T---------- ------.---...----------V- ---I-K---Q---------------
     794  --------------I---M------ ------.---...--D-------M- -----K---L-------E-------
     423  -------D------V----C----- ------.---...----------M- ----GK-------------------
     379  ---A----------V---M------ ------.-S-...----A-----V- ---I-K---Q-------Q-------
    1428  ---------A----T---R------ ------.-T-...-.---D----V- -----K-------------------
     292  --------------I----C----- ------.---...----------V- -----K-----------Q-------
    1096  ---A------Y---I---------- -----E.--E...--N-DG----L- -------------V----------L
     984  ----------Y---I---------- -----E.--E...--D-DG----L- -------------V----------L
    1543  --------------I---------- -----E.---...-..-E-----L- ---I-K-----------K--H----
    LF-1  --L-----------V---M------ -----N.---...-E-GD-VN--L- ------------------------H
     138  -------S------V---------- ------.---...DDDG..----L- ----N-L-----------------H
      EP  --------------I---R------ ------.---...--D-DG----M- -----K-----R-------------
    1268  ---A----------I---------- -----E.---...DANNS-----M- ---I-N-----------K---K--H
    1567  ---A----------T---M------ --E--E.---...DDDGD..---L- -----G--------------SR---
      PL  ---A----------V---M------ -----E.---...----------M- ---Q-K-----------K--S---L
     546  --------------I---MT----- -----S-L-G-...E--DG----L- ----G-------------------H
     511  ---A----------V---M------ -----GALLE-...E--DG----M- -----K-N---------K--S----
    1069  -------D--Y---V----T----- -----S-L-E---DE--DG--Y-L- -----K-------P----------L
   117-1  -------E------I----Q----- ------.--E...-EG-DG----L- ----G---------------H----
    1378  --------------V---------- ------.---...-E-----N--L- -----P-----R-R----------H
RLAFHHVARELHPEYF****KNC$
RLALRHIAREQHPEYY****KD$
TYEAYVRYPEEFGSKSGLSEEEVRR RLTARGLLNMADKKET
SYEAFIRYPEEFGHKSGLPEEEWKA RLKARGIPFS
DYTAFVRYPEEFGHKSGLPEEEWKA RLKARGIPFSSTLR
                      250           264
--K--QL------YQ---A-K---- K-------CR---
K-E--T-------Y---M------- K-------CR---
-----N--------N-----K---- --------CR---
-----N--------N-----K---- --------CR---
--A--N--------N-----K---- --------CR---
S-----KH------N-----N---- ----------*
E----KQ-----K-------D---- ---------N*
--V--T------------------- ----------*
S-----KH----------------- ---------N*
N-V--NL------Y------K--R- K---------E*
--V--NL------YQ-----K---- K---------E*
--I--RL------YQ---------- K---------E*
N-V--NL-------------K---- K---------E*
--V--RL------------------ ----------*
--V--RL------------------ K--------N*
--V--KKH----------------- ----------*
--E--K-H----------------- ---------*
--V--RL-------------D---- ----------*
--E--T------K-------D---- ----------*
--K--TL-----R-------D---- --------CRL--
-----T------K------------ ---------D*
N-E--N-------Y----------- ---------H*
S-E--T-------YQ---------- ----------*
E------------Y--D---DV--- K---------
E------------Y--D---DV--- K---------*
E------------YQ-----D---- K---------*
E------------------------ --------CR----
E------H-----Y----------- ----------*
E-K--NL------------------ ----------*
--V--D-------YQ---------- ----------*
E-----K------Y----E------ ----------*
Q-----KH------------K--Q- ----------*
E-K---LH----------------- ----------*
E-K--TL------------------ K--------N*
N-K--NL------Y------K---- K---------*
E-----K-----R-------K---- K--------E*
E-----K------Y---------R- ---------N*
Fig. 2. Alignment of the nef gene amino acid sequence of 37 HIV-2 infected individuals in the Portuguese cohort related to
HIV-1, SIVCPZ, SIVMAC, HIV-2ROD and the Portuguese HIV-2 nef consensus sequence. Sites important for nef function from
the N- to the C-termini are highlighted for the different groups as follows: 1, myristoylation site; 2, N-terminal helix and putative
MHC-I downregulation site; 3, tyrosine-based adaptor protein (AP) recruitment motif; 4, CD4-binding site (as characterized
for HIV-1); 5, acidic cluster (MHC-I downregulation); 6, proline-based repeat sequence (MHC-I and SH3 binding); 7, PAK
binding; 8, COP-1 recruitment; 9, di-leucine-based AP recruitment (HIV-1 nef); and 10, V-ATPase and Raf-1 binding.
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individuals (aa 185–195, Fig. 2), covering a putative site
for b-COP recruitment. However, there was no apparent
relationship between this variability and disease status.
(iii) Putative SH3-binding domains characterized by
proline-rich (PxxP) motifs. The proline-rich motif
(P104xxPLR) was assessed for variation in more detail.
Within this core region, R105RK was observed frequently
among these Portuguese sequences to form the sequence
P104KVPLR, with the arginine residue at position 109.
This adds to the observation that this region, which
mediates interaction with SH3 ligands, is evolutionarily
conserved among primate lentiviruses and is present as
a minus-orientation binding consensus. Moreover, HIV-2
nef sequences generated in this study exhibited a broad
range of PxxP configurations (Fig. 2, Table 2). An HIV-1-
like (PxxP)3 configuration was observed for six indivi-
duals (16?2%), three asymptomatic (MP, 511 and 293)
and three symptomatic (281, 956 and 379). Conversely,
disrupted minimal PxxP motifs were associated exclu-
sively with an asymptomatic profile (11/26, 42?3%),
where the P107 residue was mutated to glutamine in nine
individuals (PL, 1567, 1215, 1570, 1147, 794, 1268, 741
and 1139) and the P104 residue to serine in two (120
and 292), the only individuals not preserving the pro-
line at position 104. Disruption of the core P104xxPLR
region, P107RQ (n=9) and P104RS (n=2) was associated
strongly with an asymptomatic phenotype, although
patient PL who had been infected for 24 years had a
relatively low CD4 count in 1997 (127 cells mm23). The
tyrosine (Y145) forming part of a putative hydrophobic
pocket (Y145LEKE149E150) distal to the PxxP region impli-
cated in SH3 binding in HIV-1 nef (Collette et al., 2000)
was absolutely conserved, with minimal changes to other
residues associated with this motif, with E149 mutated to
either a glutamine or a lysine in patients 1543 and 1567
and E150 mutated to lysine in patient 223; all three indivi-
duals were asymptomatic. In addition, there was an
I144RL substitution in six individuals (281, MP, 120, 984,
1428 and 1096) immediately prior to Y145 and similar
mutations in three other individuals: I144RT (n=2) and
I144RM (n=1), although the significance of these changes
is not known. Other sequences associated with the
(PxxP)3 region in HIV-1 is a phenylalanine residue (F
122).
In HIV-2, this appeared in four individuals (281, 120, MP
and 741), although the consensus of the comparable resi-
due is a valine. No additional PxxP motifs in other regions
of nef were identified in any of these HIV-2 sequences.
Variability in the central PxxP region was investigated
further for associations with disease status and virus load.
Relationship between PxxP sequence and
plasma virus load
The spectrum of proline configurations observed in these
patients was related to HIV-2 viral RNA levels determined
for 27 different individuals at the first time-point
(Table 2). Overall, HIV-2 virus load was low, reflecting
the high proportion of asymptomatic persons, with 77?7%
(21/27) having ¡500 copies ml21 and 59?3% (16/27)
having ¡200 copies ml21. Only 3 of 21 individuals
with ¡500 copies plasma RNA ml21 were symptomatic
(patients 423, 546 and 268). Of these, patient 423 had a CD4
count of 996 cells mm23 and patients 546 and 268 had
counts of 297 and 340 cells mm23, respectively. There was a
non-significant trend for increasing levels of HIV-2 RNA
with additional prolines, although the number of individuals
with high virus load was small, with only three individuals
having relatively high levels of HIV-2 RNA (patients 379,
1069 and 984), with 62 950, 34 750 and 8830 copies ml21,
respectively; all three were symptomatic. Of four indivi-
duals who possessed the tetra-proline motif and for whom
virus load data were available, two (patients 379 and 117-2)
had high virus loads; the other two individuals (511 andMP)
had low/undetectable virus loads and were asymptomatic,
with CD4 counts of 473 and 610 cells mm23, respectively.
Of the 20 individuals with an intact P104xxPLR motif but
not a tetra-proline configuration, eight (117-1, 423, 280,
268, 984, 138, 1069 and 546) had evidence of symptomatic
infection/AIDS. The second sample taken from patient 117
at 5 years later indicated an A107RP change, forming a
(PxxP)3 motif, and an A
106RV change. The Nef protein of
all 20 would seem to be capable of interacting with SH3 in
this region. Further subdivisions of this group indicate that
11 individuals have only the minimal P104xxPLR sequence
(n=3 symptomatic: 268, 984 and 138; n=8 asymptomatic:
1378, 223, EP, 1096, 1544, 1320, BL and LF); eight (n=4
symptomatic: 280, 1069, 423 and 117; n=4 asymptom-
atic: 1543, 1428, 483 and 1227) had an additional P101
(P101xxPxxPLR) and one symptomatic patient (546) had a
PxxPLRP110 configuration.
Finally, 11 individuals had a disruption in the central
region of the PxxP motif, mostly as a P107RQ mutation
(n=9), all of which were asymptomatic; this was statistically
significant (Fisher’s exact test, P=0?026). There was also
a non-significant trend for lower virus loads with fewer
prolines present (Table 2). Levels of viral RNA correlated
more closely to clinical status, with a significantly higher
plasma virus load in symptomatic than asymptomatic
individuals (mean HIV-2 RNA levels were 17 051 and
817 copies ml21, respectively; unpaired Student t-test,
P=0?0026), whereby all symptomatic individuals possessed
an intact core P104xxPLR motif. Conversely, disruptions to
the P104xxPLR core were associated with lower virus loads,
which only exceeded 5000 copies ml21 in one asymp-
tomatic individual (PL) who had been infected for 24
years and who had a low (127 cells mm23) CD4 count.
Longitudinal changes in nef and cloned nef
sequences
A second sample obtained from each of six individuals, two
symptomatic (281-2 and 117-2) and four asymptomatic
(LF-2, MP-2, 1147-2 and 1139-2), allowed comparison with
nef sequences from earlier time-points. The close genetic
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Table 2. Variation of the PxxP region of HIV-2 nef in the 37 HIV-2-infected individuals related to levels of plasma virus load
(27 individuals) and CD4 lymphocyte counts (25 individuals)
Mean virus load and CD4 counts are indicated for three groups categorized according to the configuration of proline residues ranging from
a tetra-proline configuration to a disrupted minimal core P104xxP107 motif. NA, Not available.
Reference HIV-2 nef sequence variation of PxxP motif
Viral RNA load
(copies ml21)
CD4 count
(cells mm23) Clinical status
Consensus P101 V T P R V P L R A110
Tetra-proline
configuration
(PxxP)3
281-1 P V T P K V P L R P NA 46 Symptomatic
379 P V T P R V P L R P 62 950 366 Symptomatic
956 P V T P R V P L R P NA 220 Symptomatic
MP-1 P V T P K V P L R P <200 610 Asymptomatic
293 P V T P R T P L R P NA 519 Asymptomatic
511 P V T P R V P L R P 500 473 Asymptomatic
Mean (n=6) 21 156 (n=3) 372 (n=6)
Intact PxxP107
sequence
138 H V T P R V P V R A NA NA Symptomatic
984 S V T P R V P L R A 8 830 195 Symptomatic
268 S V T P R V P L R E 200 340 Symptomatic
BL S V T P K T P L R E <200 288 Asymptomatic
EP A V T P K V P L R T <200 490 Asymptomatic
LF-1 S V T P K V P L R A 400 437 Asymptomatic
223 S V T P R V P L R A NA 161 Asymptomatic
1096 S V T P R V P L R A <200 902 Asymptomatic
1320 S V T P R V P L R G 200 444 Asymptomatic
1378 S V R P R V P L R A NA NA Asymptomatic
1544 H V K P R V P L R E NA 730 Asymptomatic
117-1 P V T P K A P L R A NA 199 Symptomatic
280 S V T P R V P L R T NA NA Symptomatic
423 P V T P K V P L R A <200 966 Symptomatic
1069 P V R P R V P L R T 34 750 NA Symptomatic
483 P V T P R V P L R A 200 NA Asymptomatic
1227 P V T P R V P L R E <200 NA Asymptomatic
1428 P V S P R V P L R E <200 NA Asymptomatic
1543 P V T P Q V P L R Q <200 993 Asymptomatic
546 S V T P R V P L R P <200 297 Symptomatic
Mean (n=20) 3 195 (n=14) 495 (n=13)
Disrupted minimal
motif P104/P107
PL S V V P R V Q L R I 6 920 127 Asymptomatic
741 P V V P R V Q L R E <200 NA Asymptomatic
794 P V T P R T Q L R E <200 NA Asymptomatic
1139-1 S V R P K V Q L R A <200 NA Asymptomatic
1147-1 A V T P K V Q L R A 2 259 407 Asymptomatic
1215 S V T P R V Q L R G <200 430 Asymptomatic
1268 S V T P R V Q L R A 3 730 529 Asymptomatic
1567 P V T P R V Q L R E 3 491 1 346 Asymptomatic
1570 S V T P R V Q L R G <200 427 Asymptomatic
120 P V T S R V P L R P NA NA Asymptomatic
292 S V T S R V P L R A <200 NA Asymptomatic
Mean (n=11) 1 650 (n=10) 544 (n=6)
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relationship between the two sequences (Fig. 1) indicated
no difference in nef sequence measured at two distinct time-
points. However, some evidence for increased nucleotide
distances was observed, relating to sampling times that
ranged from 0?6 to 1?5% for 6 months to 1 year (sequences
1147-1/1147-2, 1139-1/1139-2 and 281-1/281-2), 1?6–2?4%
at 3 years (LF-1/LF-2 and MP-1/MP-2) and 3?4% for a 5
year break between sampling (117-1/117-2). These findings
(approximately 0?5–1% per year) are similar to values
estimated previously (Shankarappa et al., 1999; Pieniazek
et al., 1999).
Clones isolated from three patients with disparate nef
sequences were also sequenced: one AIDS patient (sample
117-2), one asymptomatic individual (sample MP-2) and
one asymptomatic individual (1268) with disruptions
in both proline-rich and di-leucine regions. No major
variation in nef sequence, either synonymous or non-
synonymous, was identified in individual clones compared
to bulk sequence derived from a ‘swarm’ of proviruses and
overall, the cloned data confirmed the observed changes in
nef sequence to be present as majority sequence (Fig. 3).
DISCUSSION
The natural variability of nef and its relation to putative
nef function in HIV-2-infected individuals, where there is
a higher proportion of long-term survivors compared to
HIV-1, is not well documented. One previous study of
HIV-2 nef sequences reported a higher frequency (10–15%)
of disrupted nef alleles in asymptomatic HIV-2-infected
individuals (Switzer et al., 1998), implying a role for nef in
the pathogenesis of HIV-2 infection. In this cross-sectional
analysis of HIV-2-infected individuals living in Portugal, we
found little evidence of major nef disruption, akin to the
situation in HIV-1, whereas more discrete changes in nef
sequence likely to impact on specific aspects of nef function
were identified. All HIV-2 nef sequences were of a single
subtype (A), reflecting the demographical links with Guinea
Bissau (Grassly et al., 1998) and contrasting with the wide
spectrum of nef sequences from HIV-1 group M (Jubier-
Maurin et al., 1999). Interestingly, two of the six disrupted
sequences described by Switzer et al. (1998) were HIV-2
subtype B infections, not subtype A, originating from the
Ivory Coast where HIV-2 subtype B is prevalent (Pieniazek
et al., 1999). Hence, truncation as a feature of nef disruption
per se seems unlikely to account for the higher proportion of
attenuated HIV-2 phenotypes observed frequently, parti-
cularly if the infecting virus belongs to subtype A. Similarly,
LTR structures containing core promoter and enhancer
elements important in gene regulation and virus expression
(Clark et al., 1995; Leiden et al., 1992; Markovitz et al., 1992)
were also intact with a subtype A identity and conserved
in vivo (Berry et al., 2001).
Studies of SIVMAC have indicated that subtle differences in
nef can alter dramatically the in vivo characteristics of virus
replication (Whatmore et al., 1995) and a broad body of data
exists relating the structure of HIV-1 nef with functional
characteristics (Geyer et al., 2001; Piguet & Trono, 1999).
Sequence-specific motifs involved in key functions of nef,
such as enhancement of virus infectivity, downregulation of
CD4 and interaction with T-cell signalling pathways, have
the potential to invoke a variety of cellular pathways that can
have an impact on pathogenesis. Hence, we embarked on a
more systematic study of the HIV-2 nef sequence based on
known properties of HIV-1 or SIV nef.
Key features of nef function, such as the myristoylation
signal, were absolutely conserved among HIV-2 sequences,
re-enforcing the notion that N-myristoylation is critical for
the biological activity of all nef proteins (Harris, 1995).
Fig. 3. Phylogenetic tree of nef sequences derived from 20 indi-
vidual clones (CL) obtained from three HIV-2-infected individuals
(117, 1268 and MP), five reference HIV-2 subtype A sequences
(HIV-2BEN, HIV-2ALI, HIV-2ISY, HIV-2ROD and HIV-2ST) and three
reference sequences for subtype B (HIV-2EHO, HIV-2ALT/D205 and
HIV-2UC1). SIVMM239 was used as the outgroup sequence. Data
obtained from bulk sequence analysis (117-1, 281-1, 1268 and
MP-1). The suffix ‘dil’ indicates sequences derived from an original
1/10 dilution of template DNA. The majority of clones from
patients 117 and MP were obtained from the second time-point
(117-2 and MP-2). Bootstrap values above 80%, based on 100
replicates, are indicated at the branching nodes. Evolutionary
distances were estimated using the Kimura two-parameter model
and genetic relationships were determined using the neighbour-
joining method. Bar, 10% sequence divergence.
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Analysis of motifs in HIV-2 nef indicated no difference
in N-terminal tyrosine-based sorting signals, with no
additional tyrosine residues, such as RQRYE (YE nef),
which, under certain circumstances, have been linked to
acute lymphocyte activation and pathogenicity of some
strains of SIV involving SH2 interactions (Luo & Peterlin,
1997). Interestingly, interactions of SIV nef with human Lck
or Hck do not seem to bemediated via the consensus proline
motif, as is the case for HIV-1 nef (Collette et al., 1996), as
SIV nef demonstrates the ability to bind Lck and Hck SH2
domains, suggesting the multiple mechanisms by which nef
is able to bind to and regulate Src kinases (Greenway et al.,
1999). The role of Src family kinases and the interaction with
either SH2 or SH3 remains to be clarified for HIV-2.
In this respect, the natural variability of proline sequences
that could mediate putative SH3 interactions was an import-
ant finding in this study. This variability was wider than that
recognized previously and appeared to be related, at least
in part, to disease status. There was a significant correlation
between a P107RQmutation at the centre of the P104xxPLR
core and an asymptomatic phenotype, which formed one
end of a wide spectrum of proline configurations. Though
numbers were relatively small, an increased number of
proline residues was accompanied by increased virus load.
However, tetra-proline (PxxP)3 sequences in three asymp-
tomatic individuals were also identified and RNA levels in
5/6 patients with (PxxP)2 motifs were below the level of
detection. Moreover, the wide spectrum of PxxP configur-
ations encompassed all theoretical combinations ranging
from (PxxP)3 to P
104xxQ. This situation contrasts markedly
with HIV-1 where, even in studies of long-term survivors,
the consensus tetra-proline motif remains preserved, with
no difference in proline motif configurations between rapid
progressors and long-term survivors (Kirchhoff et al., 1999).
Interestingly, in studies of SIV-infected macaques, there
appears to be a strong selection pressure for a functional
SH3-binding ligand in vivo, associated with kinase interac-
tions (Khan et al., 1998), although other studies cast doubt
on the functional significance of the PxxPmotif in leading to
disease induction during the acute phase (Lang et al., 1997).
However, the latter study seems unlikely to be representative
of the broader picture of disease development in simian
AIDS. Moreover, studies in the TgCD4 mouse model for
HIV-1 nef have identified the PxxP region to be a crucial
determinant of pathogenicity (Hanna et al., 2001). The
natural variability of proline-rich sequences in these HIV-2-
infected individuals is compelling, given the potential for
this region to interact with a variety of cellular partners
and to modulate virus replication at the level of the T-cell
receptor signalling environment (Fackler et al., 2001). The
fact that a P107RQ mutation was found only in asymp-
tomatic individuals who also had low levels of peripheral
viral RNA suggests a role for PxxP–SH3 interactions in
influencing pathogenesis. Hence, one could envisage a
situation where the secondary structure of the polyproline
type II helix is stabilized by the additional proline residues,
with the critical P104xxP107 providing the important hydro-
phobic contacts with binding of the SH3 domain. The trend
for increasing plasma virus load with increasing numbers
of proline residues may reflect this and disruption of the
binding consensus would have a major impact on putative
SH3 interactions.
Immunological control also seems more effective for HIV-2
than HIV-1 (Whittle et al., 1998), with lower levels of
immune activation and reduced levels of apoptosis (Michel
et al., 2000) reflecting the low virus steady-state of many
HIV-2 infections (Andersson et al., 2000; Ariyoshi et al.,
2000; Berry et al., 1998, 2002; Popper et al., 1999). Recent
data have indicated a role for nef in apoptotic regulatory
pathways (Geleziunas et al., 2001; Wolf et al., 2001; Fackler
& Baur, 2002) and aspects of cell signalling that may have a
bearing on virulence (Simmons et al., 2001). Functional data
are required to determine which cellular signalling pathways
may be involved and define a more precise role for HIV-2
nef PxxP–SH3 interactions. Whether changes in a single
region or gene such as nef might be expected to influence
pathogenicity directly in the face of multiple virus–host
interactions, including immunological considerations, is
an interesting question. Certainly, the natural variation
observed in the PxxP region was unexpected and would
suggest that this region may be one of the more relevant
regions for HIV-2 nef function in vivo. Molecular clones
derived from this study are currently being taken forward
to address some of these issues in order to provide a
fuller understanding of the role of nef in the pathogenesis of
HIV-2 infections.
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